ab248
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05653882)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2 receptor beta chainINHIBITOR
IL2RB inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300475 | Phase 1 | Mar 31, 2026 | Washington University in St. Louis |
| NCT06996782 | Phase 1/Phase 2 (Phase 2) | Oct 13, 2025 | AstraZeneca |
| NCT07037758 | Phase 1 | Sep 16, 2025 | Amgen, Asher Biotherapeutics, Inc. |
| NCT05653882 | Phase 1 | Dec 31, 2022 | Asher Biotherapeutics, Inc., Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asher Biotherapeutics, Inc. | For profit | 2 | 1 | 1 | 2022 |
| Amgen | For profit | 1 | 1 | 1 | 2025 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2026 |
5 organizations
Page 1 / 1